Compare MLAB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | ACHV |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.9M | 726.5M |
| IPO Year | 1995 | 2018 |
| Metric | MLAB | ACHV |
|---|---|---|
| Price | $128.45 | $7.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $94.00 | $14.67 |
| AVG Volume (30 Days) | 107.9K | ★ 1.4M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 436.11 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $5.41 | N/A |
| P/E Ratio | $258.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.48 | $2.62 |
| 52 Week High | $132.70 | $8.64 |
| Indicator | MLAB | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 64.58 | 56.09 |
| Support Level | $94.20 | $4.11 |
| Resistance Level | $132.70 | $8.63 |
| Average True Range (ATR) | 4.19 | 0.38 |
| MACD | -0.55 | -0.05 |
| Stochastic Oscillator | 75.66 | 55.83 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.